Related Experiment Videos
1,4-dibenzylpiperazines possess anticocaine activity.
Abby Foster1, Huifang Wu, Weibin Chen
1Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 North Pine Street, Baltimore, MD 21201, USA.
Bioorganic & Medicinal Chemistry Letters
|March 18, 2003
Summary
Researchers modified N,N-dibenzylpiperazines to boost anticocaine effects. While sigma-1 receptor affinity increased, anticocaine activity correlated better with sigma-2 binding, suggesting a new therapeutic target for cocaine addiction.
Area of Science:
- Pharmacology
- Neuroscience
- Medicinal Chemistry
Background:
- N,N-dibenzylpiperazines exhibit significant affinity for sigma receptors.
- Sigma receptors are implicated in various neurological processes and drug addiction.
- Enhancing anticocaine activity is a key goal in addiction research.
Purpose of the Study:
- To synthesize novel N,N-dibenzylpiperazine derivatives with potentially enhanced anticocaine activity.
- To investigate the relationship between sigma receptor binding affinities (sigma-1 and sigma-2) and the anticocaine efficacy of these compounds.
- To explore the potential of sigma-2 ligands in the context of cocaine addiction treatment.
Main Methods:
- Synthesis of novel N,N-dibenzylpiperazine analogs.
- In vitro binding assays to determine affinity for sigma-1 and sigma-2 receptors.
- In vivo testing of compounds for their ability to attenuate cocaine-induced convulsions in animal models.
Main Results:
- The synthesized ligands demonstrated high affinity for sigma-1 receptors.
- Anticocaine activity in attenuating cocaine-induced convulsions did not directly correlate with sigma-1 binding affinity.
- A stronger correlation was observed between anticocaine activity and sigma-2 binding affinity.
Conclusions:
- Modifications to N,N-dibenzylpiperazines can yield ligands with high sigma-1 affinity.
- Sigma-1 receptor affinity alone may not predict anticocaine efficacy.
- Sigma-2 receptor binding affinity appears to be a more critical factor for the anticocaine activity of these compounds, suggesting sigma-2 receptors as a potential therapeutic target for cocaine abuse.